ATRC AtriCure, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model centers on medical devices for cardiac surgery and related treatments
• • Enhanced emphasis on cybersecurity risk management aligning with NIST Cybersecurity Framework and Zero Trust principles this fiscal year
• • Integration of cybersecurity risk assessments into enterprise risk management with Board oversight introduced or strengthened
• • Annual reviews of third-party service providers’ SOC 1 and SOC 2 reports to manage supply chain cybersecurity risks
• • Noteworthy focus on potential material adverse effects of cybersecurity incidents on business and financial outcomes

Risk Factors

• • No specific or timely regulatory or legal risks detailed beyond general cybersecurity oversight frameworks
• • No geopolitical or macroeconomic threats identified with concrete exposure details
• • Cybersecurity risk management reliant on a limited IT leadership team with combined 60 years experience, potential expert concentration risk
• • No competitive or market disruption risks mentioned involving named competitors or new technology
• • No financial or structural risks such as leverage, concentration, or key-person dependencies explicitly highlighted

Management Discussion & Analysis

• • Revenue $534.5M, up 14.9% YoY ($465.3M in 2024); growth driven by pain management (+32.5%), open ablation (+16.3%), appendage management (+17.5%), minimally invasive ablation declined (−31.2%)
• • Gross margin 75.0% vs 74.7%, up 29 basis points; operating margin loss improved to −1.8% vs −8.6%; net loss narrowed to $11.4M (−2.1%) vs $44.7M (−9.6%)
• • Best segment: Appendage management revenue $178.1M, +17.5% YoY; worst: Minimally invasive ablation $31.5M, down 31.2%
• • Operating cash flow increased by $45.1M; financing inflows include $6.25M sale-leaseback; cash $167.4M; debt $61.9M with $61.9M borrowing capacity; capex ongoing for facility expansion
• • Management expects continued product innovation, clinical trial progress (LeAAPS, BoxX-NoAF), monitors inflation risks, and maintains liquidity via credit facility and shelf registration

What are the latest ATRC SEC filings in 2026?

AtriCure, Inc. (ATRC) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on July 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ATRC file its most recent 10-K annual report?

AtriCure, Inc. (ATRC) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ATRC 10-Q quarterly reports?

AtriCure, Inc. (ATRC)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every ATRC 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ATRC filed recently?

AtriCure, Inc. (ATRC)'s most recent 8-K was filed on July 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ATRC insider trading activity (Form 4)?

SignalX aggregates every ATRC Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ATRC file with the SEC?

AtriCure, Inc. (ATRC) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ATRC filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for AtriCure, Inc. (ATRC).

What is ATRC's SEC CIK number?

AtriCure, Inc. (ATRC)'s SEC CIK (Central Index Key) number is 1323885. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1323885 to look up all ATRC filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ATRC return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from AtriCure, Inc. (ATRC) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.